Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide - Wikidata - wikimedia - TriplyDB

Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide

Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide

http://www.wikidata.org/entity/Q27666404

about

Expanding the clinical indications for α(1)-antitrypsin therapy Integrated analysis of residue coevolution and protein structures capture key protein sectors in HIV-1 proteins A novel small-molecule inhibitor of HIV-1 entry The three lives of viral fusion peptides Discovery of modulators of HIV-1 infection from the human peptidome.Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells The role of serpin and cystatin antiproteases in mucosal innate immunity and their defense against HIV.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.Proteins, peptides, polysaccharides, and nucleotides with inhibitory activity on human immunodeficiency virus and its enzymes.Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor.Structural Study of a New HIV-1 Entry Inhibitor and Interaction with the HIV-1 Fusion Peptide in Dodecylphosphocholine Micelles.A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity.The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity.Increased prevalence of the alpha-1-antitrypsin (A1AT) deficiency-related S gene in patients infected with human immunodeficiency virus type 1.The KT Jeang Retrovirology prize 2016: Frank Kirchhoff.Novel therapeutic uses of alpha-1 antitrypsin: a window to the future.Tumor necrosis factor-α driven inflammation in alpha-1 antitrypsin deficiency: a new model of pathogenesis and treatment.Development of peptide inhibitors of HIV transmission.

P2860

Q27000764-9FE5044E-FBBD-4067-B7DF-2CD3BB6DEF6C Q28543396-A48E05C1-75E6-4321-A999-15EBD9BC9CDD Q28606625-65353912-8368-41E9-85BA-C58F03F332A3 Q33770459-4C1A1C2E-03ED-4721-A03A-13104F798D3E Q35222585-BCD3E914-91FD-47BD-97FE-AC639CF52B04 Q37372512-D56EA4D4-2087-44BB-8997-1D414C9AB209 Q38170193-9C99E880-CC9B-4AD2-A3A2-4150A5218100 Q38196457-F611604E-D824-4C47-A981-B5E4D0A38B9E Q38574172-92C6589D-7C93-4BFD-81D8-11E818FE2CC9 Q38593985-75B8F391-94F0-464E-82C1-D6F92F1E2D6F Q39361526-CA7217D4-41EC-4826-9BCB-A35EFB9717F8 Q39365785-2C370C20-46F5-4B8F-A9B2-993A07797CC5 Q39698701-E864BA15-D111-411B-A8AB-2A5EA1A1431A Q40134876-17D76CEF-CE4D-4B17-AD4B-12C5B151EB70 Q40267838-616D6708-0E12-406F-832F-FF64F1858E9A Q42234561-516D4A04-9475-4898-A449-FD5868F39D46 Q42262698-DCCBAA34-1DDF-4702-B422-AFC371A46A2D Q42379656-6AF72AD7-EA32-48E9-803F-6F441A337A7A Q51534901-27522103-81F4-4F9E-BBF0-92AA4BF2118D Q51568269-249B6BAF-C20E-4276-B781-5079B47BCC21 Q55317261-537119D1-A2CB-421B-B31E-86FA2E8854CA

P2860

Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide

http://www.wikidata.org/entity/Q27666404

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Short-term monotherapy in HIV- ...... gainst the gp41 fusion peptide

@ast

Short-term monotherapy in HIV- ...... gainst the gp41 fusion peptide

@en

Short-term monotherapy in HIV- ...... gainst the gp41 fusion peptide

@nl

type

label

Short-term monotherapy in HIV- ...... gainst the gp41 fusion peptide

@ast

Short-term monotherapy in HIV- ...... gainst the gp41 fusion peptide

@en

Short-term monotherapy in HIV- ...... gainst the gp41 fusion peptide

@nl

prefLabel

Short-term monotherapy in HIV- ...... gainst the gp41 fusion peptide

@ast

Short-term monotherapy in HIV- ...... gainst the gp41 fusion peptide

@en

Short-term monotherapy in HIV- ...... gainst the gp41 fusion peptide

@nl

P1433

Q27666404-D4DD22DA-4775-4BC1-BC08-4976EC1AB56B

P1476

Q27666404-BFBA30EF-D13B-4D72-9532-D27FB9E1046D

P2093

Q27666404-062F71F5-E413-4BC9-897D-F997EB302CB6

Q27666404-1031CF1C-5C3D-4CA6-86A1-FD09EF048428

Q27666404-3BA96124-C304-476D-85F2-1BD1E91ED653

Q27666404-54AD646C-6790-4B31-B13F-6EAC45CCD5DB

Q27666404-5D07BD95-2E54-4F12-AFC7-7FFA32C9657B

Q27666404-5E5E6869-09CD-4C48-AA5A-672D6E85962D

Q27666404-80FDF3DC-39C7-4817-BAF3-EA382712BB96

Q27666404-9762E3F9-BEC4-4922-A060-A80A445BED28

Q27666404-A6AB0271-2723-4DF4-992A-0405FD6FCE1B

Q27666404-C623E1FF-ADAA-4C16-B7B5-7B6198175F9A

P2860

Q27666404-09F78F0E-ECD2-4C7A-9D6D-E3DBD9F598D7

Q27666404-2A48D5D3-D29C-4CB2-846A-E624D7FA9310

Q27666404-310FAA6E-8916-40A9-B158-466F2F71E298

Q27666404-31D9843C-B0BC-4AC5-8605-6E625D37180B

Q27666404-3755E71F-E880-4DE8-879C-8563413DAB2B

Q27666404-3FCF1975-8D5A-4CD8-BB45-DD3C951FCF89

Q27666404-4EEDE30E-9679-4537-B21C-E729145D234E

Q27666404-583CE98F-45BA-412A-B133-EED59D3FDB94

Q27666404-82EDB104-4763-4FCA-9F9E-285258CA2E6E

Q27666404-85A83E52-3543-4C6B-BC32-AA70468A8430

P304

Q27666404-C675C69A-B22B-4386-ABD8-633F6F885EE3

P31

Q27666404-F1BF5104-6A41-4D6D-A67E-F5D2F7A483E2

P3181

Q27666404-07D917DA-5E0A-4654-A62C-50D5572BE104

P356

Q27666404-2656B7C2-FF7F-40F8-A982-B27FB551CDDE

P407

Q27666404-79D2BB53-035E-4FB5-A9DE-393C52E313F4

P433

Q27666404-E385FF74-EB9A-4F96-ABE9-C2DDC89D3B71

P478

Q27666404-1FD04109-AAFB-420A-90FB-5FFB8594B207

P50

Q27666404-5E80BCE4-A4AA-449C-A0B1-07A0A1C22E60

Q27666404-6EE018A8-5D6D-4FC3-A9B0-7606E1541614

Q27666404-6EE0A62E-0C74-4325-84BD-8128E38443B9

Q27666404-A420931B-F189-4BC8-B9D8-424E192BCA6B

P577

Q27666404-996AE867-9CFE-4A87-89E6-CE1EB9774A4F

P5875

Q27666404-371F2239-87D9-44D2-B126-3E8B5487766C

P698

Q27666404-85EFBC54-B5B1-4535-B701-68753D54218F

P921

Q27666404-513F7716-3718-40E0-8055-B74285D2E127

Q27666404-C6D8F406-CCB5-4939-ADCE-4329FC7E543D

P3181

P356

SCITRANSLMED.3001697

P1433

Science Translational Medicine

P1476

Short-term monotherapy in HIV- ...... gainst the gp41 fusion peptide

@en

P2093

Angeles Canales-Mayordomo

http://www.w3.org/2001/XMLSchema#string

Annette Busmann

http://www.w3.org/2001/XMLSchema#string

Dirk Meyer-Olson

http://www.w3.org/2001/XMLSchema#string

Hanns-Christian Tillmann

http://www.w3.org/2001/XMLSchema#string

Jan Münch

http://www.w3.org/2001/XMLSchema#string

Javier Pérez-Castells

http://www.w3.org/2001/XMLSchema#string

Jesus Jiménez-Barbero

http://www.w3.org/2001/XMLSchema#string

Jochen Hirsch

http://www.w3.org/2001/XMLSchema#string

Kleomenis Barlos

http://www.w3.org/2001/XMLSchema#string

Knut Adermann

http://www.w3.org/2001/XMLSchema#string

P2860

Structures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common Theme

Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide

CgNa, a type I toxin from the giant Caribbean sea anemone Condylactis gigantea shows structural similarities to both type I and II toxins, as well as distinctive structural and functional properties 1

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

Engineering chemokines to develop optimized HIV inhibitors.

Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection

An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion.

Resistance to enfuvirtide, the first HIV fusion inhibitor.

Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.

P304

63re3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4115417

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCITRANSLMED.3001697

http://www.w3.org/2001/XMLSchema#string

P407

P433

63

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Frank Kirchhoff

Ludger Ständker

Guillermo Giménez-Gallego

Wolf-Georg Forssmann

P577

2010-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49702241

http://www.w3.org/2001/XMLSchema#string

P698

21178138

http://www.w3.org/2001/XMLSchema#string

P921

membrane fusion involved in viral entry into host cell